Trial Profile
A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2026
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; PF 07985045 (Primary) ; PF-07284892 (Primary) ; Sasanlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 22 May 2026 Status changed from active, no longer recruiting to discontinued.
- 14 Jan 2026 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2025 Number of treatment arms are increased from 11 to 12 by the addition of Experimental: Part 2 Cohort B4 arm.